293 related articles for article (PubMed ID: 16847290)
41. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity.
Gokcel A; Gumurdulu Y; Karakose H; Melek Ertorer E; Tanaci N; BascilTutuncu N; Guvener N
Diabetes Obes Metab; 2002 Jan; 4(1):49-55. PubMed ID: 11874442
[TBL] [Abstract][Full Text] [Related]
42. Weight loss and quality of life improvement in obese subjects treated with sibutramine: a double-blind randomized multicenter study.
Di Francesco V; Sacco T; Zamboni M; Bissoli L; Zoico E; Mazzali G; Minniti A; Salanitri T; Cancelli F; Bosello O
Ann Nutr Metab; 2007; 51(1):75-81. PubMed ID: 17356258
[TBL] [Abstract][Full Text] [Related]
43. Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction.
Zannad F; Gille B; Grentzinger A; Bruntz JF; Hammadi M; Boivin JM; Hanotin C; Igau B; Drouin P
Am Heart J; 2002 Sep; 144(3):508-15. PubMed ID: 12228789
[TBL] [Abstract][Full Text] [Related]
44. The Long-term Outcomes of Sibutramine Effectiveness on Weight (LOSE Weight) study: evaluating the role of drug therapy within a weight management program in a group-model health maintenance organization.
Porter JA; Raebel MA; Conner DA; Lanty FA; Vogel EA; Gay EC; Merenich JA
Am J Manag Care; 2004 Jun; 10(6):369-76. PubMed ID: 15209480
[TBL] [Abstract][Full Text] [Related]
45. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial.
Wadden TA; Berkowitz RI; Womble LG; Sarwer DB; Arnold ME; Steinberg CM
Obes Res; 2000 Sep; 8(6):431-7. PubMed ID: 11011909
[TBL] [Abstract][Full Text] [Related]
46. Influence of weight reduction by sibutramine on female sexual function.
Kim KK; Kang HC; Kim SS; Youn BB
Int J Obes (Lond); 2006 May; 30(5):758-63. PubMed ID: 16404407
[TBL] [Abstract][Full Text] [Related]
47. Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia.
Dujovne CA; Zavoral JH; Rowe E; Mendel CM;
Am Heart J; 2001 Sep; 142(3):489-97. PubMed ID: 11526363
[TBL] [Abstract][Full Text] [Related]
48. Psychobehavioral and nutritional predictors of weight loss in obese women treated with sibutramine.
Hainer V; Kunesova M; Bellisle F; Hill M; Braunerova R; Wagenknecht M
Int J Obes (Lond); 2005 Feb; 29(2):208-16. PubMed ID: 15583700
[TBL] [Abstract][Full Text] [Related]
49. Comparison of methods for delivering a lifestyle modification program for obese patients: a randomized trial.
Digenio AG; Mancuso JP; Gerber RA; Dvorak RV
Ann Intern Med; 2009 Feb; 150(4):255-62. PubMed ID: 19221377
[TBL] [Abstract][Full Text] [Related]
50. A benefit-risk assessment of sibutramine in the management of obesity.
Nisoli E; Carruba MO
Drug Saf; 2003; 26(14):1027-48. PubMed ID: 14583064
[TBL] [Abstract][Full Text] [Related]
51. Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients.
Hazenberg BP
Cardiology; 2000; 94(3):152-8. PubMed ID: 11279320
[TBL] [Abstract][Full Text] [Related]
52. Use of sibutramine in obese Hispanic adolescents.
Violante-Ortìz R; Del-Rio-Navarro BE; Lara-Esqueda A; Pèrez P; Fanghänel G; Madero A; Berber A
Adv Ther; 2005; 22(6):642-9. PubMed ID: 16510381
[TBL] [Abstract][Full Text] [Related]
53. Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT).
Sharma AM; Caterson ID; Coutinho W; Finer N; Van Gaal L; Maggioni AP; Torp-Pedersen C; Bacher HP; Shepherd GM; James WP;
Diabetes Obes Metab; 2009 Mar; 11(3):239-50. PubMed ID: 18671798
[TBL] [Abstract][Full Text] [Related]
54. Effects of sibutramine-induced weight loss on cardiovascular system in obese subjects.
de Simone G; Romano C; De Caprio C; Contaldo F; Salanitri T; di Luzio Paparatti U; Pasanisi F
Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):24-30. PubMed ID: 15871847
[TBL] [Abstract][Full Text] [Related]
55. Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine.
Derosa G; Mereu R; Salvadeo SA; D'Angelo A; Ciccarelli L; Piccinni MN; Ferrari I; Gravina A; Maffioli P; Cicero AF
Intern Med; 2009; 48(5):265-71. PubMed ID: 19252346
[TBL] [Abstract][Full Text] [Related]
56. Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine.
Apfelbaum M; Vague P; Ziegler O; Hanotin C; Thomas F; Leutenegger E
Am J Med; 1999 Feb; 106(2):179-84. PubMed ID: 10230747
[TBL] [Abstract][Full Text] [Related]
57. A randomized, double-blind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder.
Appolinario JC; Bacaltchuk J; Sichieri R; Claudino AM; Godoy-Matos A; Morgan C; Zanella MT; Coutinho W
Arch Gen Psychiatry; 2003 Nov; 60(11):1109-16. PubMed ID: 14609886
[TBL] [Abstract][Full Text] [Related]
58. Long-term pharmacotherapy for obesity and overweight.
Padwal R; Li SK; Lau DC
Cochrane Database Syst Rev; 2003; (4):CD004094. PubMed ID: 14584004
[TBL] [Abstract][Full Text] [Related]
59. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects.
James WP; Caterson ID; Coutinho W; Finer N; Van Gaal LF; Maggioni AP; Torp-Pedersen C; Sharma AM; Shepherd GM; Rode RA; Renz CL;
N Engl J Med; 2010 Sep; 363(10):905-17. PubMed ID: 20818901
[TBL] [Abstract][Full Text] [Related]
60. Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial. Sibutramine Trial of Obesity Reduction and Maintenance.
Hansen D; Astrup A; Toubro S; Finer N; Kopelman P; Hilsted J; Rössner S; Saris W; Van Gaal L; James W; Goulder M;
Int J Obes Relat Metab Disord; 2001 Apr; 25(4):496-501. PubMed ID: 11319653
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
